Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face” - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Dermatological Effects and Considerations of GLP-1 Receptor Agonist Therapy: Enhanced Patient-Reported Outcomes for Inflammatory Skin Conditions Amidst the "Ozempic Face" Phenomenon

  • By

  • Saroja Rao

  • Isabella Midura

  • Kathyana P. Santiago Mangual

  • Leon I. Igel

  • Katherine H. Saunders

  • Jocelyn Carter

  • Jenny E. Murase

  • Arianne Shadi Kourosh

  • August 11, 2026

Share

Clinical Report: Dermatological Effects of GLP-1 Receptor Agonist Therapy

Overview

This study investigates patient-reported dermatologic changes associated with GLP-1 receptor agonist therapy for weight management.

Background

The use of GLP-1 receptor agonists (GLP-1RAs) has increased dramatically, particularly for weight management among non-diabetic individuals. This rise has led to heightened awareness of potential dermatologic effects.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • Patients reported improvements in inflammatory skin conditions like psoriasis and hidradenitis suppurativa while on GLP-1RAs.
  • Adverse dermatologic effects, including decreased facial volume and hair loss, were noted with higher percentages of weight loss.
  • There has been a significant increase in GLP-1RA prescriptions among non-diabetic individuals.
  • Comprehensive patient-reported outcomes regarding dermatologic effects are currently limited.

Clinical Implications

Dermatologists should be aware of both the beneficial and adverse dermatologic effects associated with GLP-1RA therapy. Educating patients about potential changes in skin and hair can help in developing comprehensive management plans.

Conclusion

The findings highlight the dual nature of GLP-1RA therapy, offering both improvements in certain skin conditions and challenges related to weight loss effects. Further research is needed to better understand these outcomes.

Related Resources & Content

  1. Glaucoma Physician, 2025 -- The Impact of GLP-1 Receptor Agonists on Ocular Disease
  2. The Medicine Maker, 2026 -- GLP-1 Analysis: Riding the Wave of Peptide Innovation
  3. JAMA Network Open -- Patient Experiences With GLP-1 Receptor Agonists
  4. New England Journal of Medicine -- GLP-1 Receptor Agonists
  5. FDA -- ZEPBOUND (tirzepatide) Injection, for subcutaneous use
  6. glaucoma physician — The Impact of GLP-1 Receptor Agonists on Ocular Disease
  7. GLP-1 Receptor Agonists | New England Journal of Medicine
  8. ZEPBOUND (tirzepatide) Injection, for subcutaneous use — Highlights of Prescribing Information
  9. JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology - PubMed

Original Source(s)

Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”

  • by Saroja Rao, Isabella Midura, Kathyana P. Santiago Mangual, Leon I. Igel, Katherine H. Saunders, Jocelyn Carter, Jenny E. Murase, Arianne Shadi Kourosh

  • August 11, 2026

Related Content

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

Understanding Social Drivers of Health Among US Adults with Psoriasis from Different Races and Ethnicities